Список литературы

1. Wu FCW, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010; 363(2): 123 - 135. doi: 10.1056/NEJMoa0911101.

2. Tajar A, Huhtaniemi IT, O'Neill TW, et al.; EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012; 97: 1508-16.

3. Алгоритмы специализированной медицинской помощи больным сахарным диабетом/Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. - 8-й выпуск. - М.: УП ПРИНТ; 2017. ISBN 978-5-91487-090-1 DOI: 10.14341/DM20171S8.

4. Beatrice A, Dutta D, Kumar M, Siddegowda K, Sinha S, Ray S, Chowdhury S. Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications//Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014:7 481 - 486. DOI https://doi.org/10.2147/DMSO.S50777).

5. Agarwal PK, Singh P, Chowdhury S, Sharma SK, Majumdar A, Shah P, et al. A study to evaluate the prevalence of hypogonadism in Indian males with Type-2 diabetes mellitus//Indian J Endocr Metab 2017; 21: 64 - 70. DOI: 10.4103/2230-8210.196008.

6. Ding E.L., Song Y., Mafk V.S., Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes. A systematic Review and Meta-analysis//JAMA, 2006.-Vol.295 (11).-p.1288-99.

7. Endocrine Society. "Previously Unrecognized Testosterone Deficiency Common In Men With Type 1 Diabetes." ScienceDaily. ScienceDaily, 27 March 2008. <www.sciencedaily.com/releases/2008/03/080326202018.htm>.

8. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocr Metab. 2010; 95(6): 2536 - 2559. doi: 10.1210/jc.2009-2354.

9. EAU Guidelines. Edn. presented at the EAU Annual Congress London 2017. ISBN 978-90-79754-91-5.

10. Zitzmann M, Faber S, Nieschlag E. Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men. J Clin Endocr Metab. 2006; 91(11): 4335 - 4343. doi: 10.1210/jc.2006-0401.

11. Tan WS, Ng CJ, Khoo EM, et al. The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men's Health Study). Aging Male 2011; 14: 231-6.

12. Tsujimura A, Miyagawa Y, Takezawa K, et al. Is low Testosterone concentration a risk factor for metabolic syndrome in healthy middle-aged men? Urology 2013; 82: 814-19.

13. Antonio L, Wu FCW, O'Neill TW, et al. Associations Between Sex Steroids and the Development of Metabolic Syndrome: A Longitudinal Study in European Men//J Clin Endocrinol Metab. 2015; 100(4): 1396 - 1404. doi: 10.1210/jc.2014-4184.

14. Araujo AB, Dixon JM, Suarez EA, et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and metaanalysis. J Clin Endocrinol Metab 2011 96(10): p. 3007-19.

15. Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen TP, Haring R, Corona G, Onat A, Maggio M, Bouchard C, Tong PC, Chen RY, Akishita M, Gietema JA, Gannage-Yared MH, Unden AL, Hautanen A, Goncharov NP, Kumanov P, Chubb SA, Almeida OP, Wittchen HU, Klotsche J, Wallaschofski H, Volzke H, Kauhanen J, Salonen JT, Ferrucci L, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies.//PLoS One. 2014; 9(7): el00409.

16. Cheung KKT, Luk AOY, So WY, et al. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. Journal of Diabetes Investigation. 2015; 6(2): 112 - 123. doi: 10.1111/jdi.12288.

17. Ho CH, Jaw FS, Wu CC, Chen КС, Wang CY, Hsieh JT, Yu HJ, Liu SP. The prevalence and the risk factors of testosterone deficiency in newly diagnosed and previously known type 2 diabetic men//J Sex Med. 2015 Feb; 12(2): 389-97. doi: 10.1111/jsm.12777.

18. Cattabiani C, Basaria S, Ceda GP, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012; 35(1): 104 - 120. doi: 10.3275/8061.

19. Lee DM, Tajar A, Pye SR, et al. Association of hypogonadism with vitamin D status: the European Male Ageing Study. European Journal of Endocrinology. 2011; 166(1): 77 - 85. doi: 10.1530/eje-11-0743.

20. Reddy RG, Aung T, Karavitaki N, Wass JAH. Opioid induced hypogonadism. BMJ. 2010; 341(aug31 1):c4462-c4462. doi: 10.1136/bmj.c4462.

21. Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Practice & Research Clinical Endocrinology & Metabolism. 2011; 25(2): 221 - 238. doi: 10.1016/j.beem.2010.08.013.

22. Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest. 2005; 28(3 Suppl): 14 - 22.

23. Курбатов Д.Г., Дубский С.А., Роживанов Р.В., Лепетухин А.Е., Шварц Я.Г. Урологические и андрологические заболевания при сахарном диабете/в кн. Сахарный диабет и репродуктивная система//под ред. академика РАН Дедова И.И., члена-корреспондента РАН Шестаковой М.В. - М.: ООО Издательство "Медицинское информационное агентство". - 2016. - С. 135 - 148.

24. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts//J Clin Endocrinol Metab 2011 Aug; 96(8): 2430-9.

25. Vesper HW, Bhasin S, Wang C, et al. Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods//Steroids 2009 Jun; 74(6): 498 - 503.

26. Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest. 2005; 28(3 Suppl): 28 - 31.

27. Bremner AP, Feddema P, Leedman PJ, et al. Age-Related Changes in Thyroid Function: A Longitudinal Study of a Community-Based Cohort. J Clin Endocr Metab. 2012; 97(5): 1554 - 1562. doi: 10.1210/jc.2011-3020.

28. Роживанов Р.В. Эндокринные нарушения половой функции у мужчин/В кн. Рациональная фармакотерапия заболеваний эндокринной системы и нарушений обмена веществ./под ред. академика РАН и РАМН Дедова И.И., академика РАМН Мельниченко Г.А. Второе издание, исправленное и дополненное. - Москва, 2013. - с. 754 - 775. [Rozhivanov RV. Endocrine disorders of sexual function in men. In: Dedov II, Mel'nochenko GA, (eds.). Rational pharmacotherapy of diseases of the endocrine system and metabolic disorders. 2nd ed. Moscow; 2013. s. 754 - 775. (in Russ.)].

29. Дедов И.И., Мельниченко Г.А., Шестакова М.В., Роживанов Р.В., Терехова А.Л., Зилов А.В., Ладыгина Д.О., Курбатов Д.Г. Рекомендации по диагностике и лечению дефицита тестостерона (гипогонадизма) у мужчин с сахарным диабетом//Ожирение и метаболизм. - 2017. - N4. - 14(4): 83 - 92.

30. Роживанов Р.В., Шурдумова Б.О., Парфенова Н.С., Савельева Л.В. Комплексный подход к лечению ожирения и метаболического синдрома у мужчин.//Ожирение и метаболизм. - 2009. - Т. 6. - N 4 - С. 38 - 41. [Rozhivanov RV, Shurdumova BO, Parfenova NS, Savel"eva LV. Kompleksnyy podkhod k lecheniyu ozhireniya i metabolicheskogo sindroma u muzhchin. Obesity and metabolism. 2009; 6(4): 38 - 41. (in Russ.)] doi: 10.14341/2071-8713-4877.

31. Роживанов Р.В. Эффективная терапия и ошибки в лечении эндокринных нарушений в андрологии/в кн. Эндокринология. Фармакотерапия без ошибок//под ред. академика РАН и РАМН Дедова И.И., академика РАМН Мельниченко Г.А. Москва, 2013. - с. 615 - 625. [Rozhivanov RV. Effective therapy and errors in treatment of endocrine disorders in andrology. In: Dedov II, Melnichenko GA, (eds.). Endocrinology. Pharmacotherapy without errors. Moscow; 2013. P. 615 - 625. (in Russ.)]

32. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement//BJU Int. 2016 Apr; 117(4): 677-85. doi: 10.1111/bju.13337.

33. Tracz MJ, Sideras K, Bolona ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials//J Clin Endocrinol Metab 2006 Jun; 91(6): 2011-6.

34. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, body metabolism and serum lipid profile in middle-aged men: a meta-analysis//Clin Endocrinol (Oxf) 2005 Sep; 63(3): 280-93.

35. Moon DG, Park MG, Lee SW, et al. The Efficacy and Safety of Testosterone Undecanoate (Nebido(R)) in Testosterone Deficiency Syndrome in Korean: A Multicenter Prospective Study. The Journal of Sexual Medicine. 2010; 7(6): 2253 - 2260. doi: 10.1111/j.1743-6109.2010.01765.x.

36. Basaria S, Lakshman KM. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging. 2009; 4: 397 - 412. doi: 10.2147/cia.s4466.

37. Johansen Taber KA, Morisy LR, Osbahr AJ 3rd, et al. Male breast cancer: risk factors, diagnosis, and management (review). Oncol Rep 2010 Nov; 24(5): 1115-20.

38. Shabsigh R, Crawford ED, Nehra A, et al. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res 2009 Jan-Feb; 21(1): 9 - 23.

39. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late onset hypogonadism: a randomized controlled trial. JAMA 2006 Nov 15; 296(19): 2351-61.

40. Medras M, Filus A, Jozkow P, et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat. 2006; 96(3): 263 - 265. doi: 10.1007/s10549-005-9074-y.

41. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010; 95(6): 2560 - 2575. doi: 10.1210/jc.2009-2575.

42. Pearl JA, Berhanu D, Francois N, et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol. 2013; 190(5): 1828 - 1833. doi: 10.1016/j.juro.2013.05.111.

43. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014; 13(10): 1327 - 1351. doi: 10.1517/14740338.2014.950653.

44. Calof OM, Singh AB, Lee ML, et al. Adverse Events Associated With Testosterone Replacement in Middle-Aged and Older Men: A Meta-Analysis of Randomized, Placebo-Controlled Trials. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2005; 60(11): 1451 - 1457. doi: 10.1093/gerona/60.11.1451.

45. Basaria S, Coviello AD, Travison TG, et al. Adverse event associated with testosterone administration//New Engl J Med 2010 Jul; 363(2): 109-22.

46. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology. 2011; 165(5): 675 - 685. doi: 10.1530/eje-11-0221.

47. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005; 130(2): 174 - 195. doi: 10.1111/j.1365-2141.2005.05535.x.

48. Роживанов Р.В., Курбатов Д.Г. Гематологические и урологические аспекты безопасности заместительной андрогенной терапии препаратом тестостерона ундеканоата пролонгированного действия у пациентов с гипогонадизмом//Проблемы эндокринологии. - 2009. - N 6, том 55. - с. 31 - 35.

49. Morgentaler A, Morales A. Should hypogonadal men with prostate cancer receive testosterone? J Urol 2010 Oct; 184(4): 1257-60.

50. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004 Sept; 172(3): 920-2.

51. Sarodsy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachitherapy. Cancer 2007 Feb; 109(3): 536-41.

52. Baillargeon J, Urban RJ, Kuo YF, et al. Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. Ann Pharmacother. 2014; 48(9): 1138 - 1144. doi: 10.1177/1060028014539918.